Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced Wednesday that it has partnered with Washington University School of Medicine in St. Louis.
The collaboration is aimed at advancing Alzheimer's disease research through a novel therapeutic strategy. It focuses on a recently submitted NIH grant proposal focused on studying HT-ALZ, an FDA-approved NK-1 receptor antagonist, for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease.
Dr. Carla M. Yuede, professor in the Departments of Psychiatry, Neurology, and Neuroscience, and director of the Animal Behavior Core at Washington University, will lead the research collaboration.
Titled 'Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement', the proposal aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval